Literature DB >> 17503127

Cognitive impairment in multiple sclerosis.

Alexander Winkelmann1, Claudia Engel, Annett Apel, Uwe K Zettl.   

Abstract

Cognitive dysfunctions are frequent symptoms of multiple sclerosis (MS) and occur in up to 65% of patients. Especially memory, attention, executive and visual constructive functions are impaired. These problems strongly affect patients' ability to work, social relationships, and quality of life. Symptoms of physical disabilities can arise independently. Cognitive dysfunctions are clear indicators of MS progression, because they represent highly complex functions that depend on the integrity of the neuronal networks. Once manifested after a relapse, they remain stable . Given a differentiating diagnosis, it is possible to treat these dysfunctions by cognitive training and with pharmaceutical drugs, for example by immunomodulating drugs. However, treatment options are limited at present. This report provides a detailed description of cognitive functions and performance in MS patients, their comorbidities such as fatigue and depression and therapeutic options.

Entities:  

Mesh:

Year:  2007        PMID: 17503127     DOI: 10.1007/s00415-007-2010-9

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  84 in total

1.  Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters.

Authors:  P Flachenecker; T Kümpfel; B Kallmann; M Gottschalk; O Grauer; P Rieckmann; C Trenkwalder; K V Toyka
Journal:  Mult Scler       Date:  2002-12       Impact factor: 6.312

2.  One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis.

Authors:  H Zéphir; J de Seze; K Dujardin; G Dubois; M Cabaret; S Bouillaguet; D Ferriby; T Stojkovic; P Vermersch
Journal:  Mult Scler       Date:  2005-06       Impact factor: 6.312

3.  Depressed mood in multiple sclerosis: relationship to capacity-demanding memory and attentional functioning.

Authors:  P A Arnett; C I Higginson; W D Voss; B Wright; W I Bender; J M Wurst; J M Tippin
Journal:  Neuropsychology       Date:  1999-07       Impact factor: 3.295

4.  Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society.

Authors:  T Henze; P Rieckmann; K V Toyka
Journal:  Eur Neurol       Date:  2006-09-08       Impact factor: 1.710

5.  A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.

Authors:  R Zivadinov; J Sepcic; D Nasuelli; R De Masi; L M Bragadin; M A Tommasi; S Zambito-Marsala; R Moretti; A Bratina; M Ukmar; R S Pozzi-Mucelli; A Grop; G Cazzato; M Zorzon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-06       Impact factor: 10.154

6.  Working memory impairment in early multiple sclerosis. Evidence from an event-related potential study of patients with clinically isolated myelopathy.

Authors:  L Pelosi; J M Geesken; M Holly; M Hayward; L D Blumhardt
Journal:  Brain       Date:  1997-11       Impact factor: 13.501

Review 7.  The neuropsychiatry of multiple sclerosis.

Authors:  Anthony Feinstein
Journal:  Can J Psychiatry       Date:  2004-03       Impact factor: 4.356

8.  Cognitive symptoms and correlates of physical disability in individuals with multiple sclerosis.

Authors:  Cira Fraser; Sharon Stark
Journal:  J Neurosci Nurs       Date:  2003-12       Impact factor: 1.230

9.  Neuropsychiatric assessment as a secondary outcome measure in a multiple sclerosis intravenous immunoglobulin L(IMg) trial.

Authors:  Y Barak; U Gabbay; R Glad; I Sarova-Pinhas; A Achiron
Journal:  Int J Psychiatry Clin Pract       Date:  1999       Impact factor: 1.812

10.  Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis.

Authors:  M Rovaris; M Filippi; M Falautano; L Minicucci; M A Rocca; V Martinelli; G Comi
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

View more
  15 in total

1.  Subcutaneous Interferon Beta-1a Has a Positive Effect on Cognitive Performance in Mildly Disabled Patients with Relapsing-Remitting Multiple Sclerosis: 2-Year Results from the COGIMUS Study.

Authors:  Francesco Patti; Maria Pia Amato; Stefano Bastianello; Luisa Caniatti; Elisabetta Di Monte; Fausto Lijoi; Benedetta Goretti; Silvia Messina; Orietta Picconi; Maria Rosalia Tola; Maria Trojano
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

2.  Monitoring my multiple sclerosis: a patient-administered health-assessment scale.

Authors:  Elsie E Gulick; Marie Namey; June Halper
Journal:  Int J MS Care       Date:  2011

3.  Changes in Fatigue and Cognition in Patients with Relapsing Forms of Multiple Sclerosis Treated with Natalizumab: The ENER-G Study.

Authors:  Jeffrey Wilken; Robert L Kane; Cynthia L Sullivan; Mark Gudesblatt; Sylvia Lucas; Robert Fallis; Xiaojun You; Pam Foulds
Journal:  Int J MS Care       Date:  2013

4.  Group cognitive rehabilitation to reduce the psychological impact of multiple sclerosis on quality of life: the CRAMMS RCT.

Authors:  Nadina B Lincoln; Lucy E Bradshaw; Cris S Constantinescu; Florence Day; Avril Er Drummond; Deborah Fitzsimmons; Shaun Harris; Alan A Montgomery; Roshan das Nair
Journal:  Health Technol Assess       Date:  2020-01       Impact factor: 4.014

5.  Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis.

Authors:  James M Stankiewicz; Bonnie I Glanz; Brian C Healy; Ashish Arora; Mohit Neema; Ralph H B Benedict; Zachary D Guss; Shahamat Tauhid; Guy J Buckle; Maria K Houtchens; Samia J Khoury; Howard L Weiner; Charles R G Guttmann; Rohit Bakshi
Journal:  J Neuroimaging       Date:  2011-04       Impact factor: 2.486

Review 6.  Ocular motor signatures of cognitive dysfunction in multiple sclerosis.

Authors:  Joanne Fielding; Meaghan Clough; Shin Beh; Lynette Millist; Derek Sears; Ashley N Frohman; Nathaniel Lizak; Jayne Lim; Scott Kolbe; Robert L Rennaker; Teresa C Frohman; Owen B White; Elliot M Frohman
Journal:  Nat Rev Neurol       Date:  2015-09-15       Impact factor: 42.937

7.  The BICAMS Battery for Assessment of Lithuanian-Speaking Multiple Sclerosis Patients: Relationship with Age, Education, Disease Disability, and Duration.

Authors:  Nataša Giedraitienė; Rasa Kizlaitienė; Gintaras Kaubrys
Journal:  Med Sci Monit       Date:  2015-12-10

8.  Contingent negative variation is associated with cognitive dysfunction and secondary progressive disease course in multiple sclerosis.

Authors:  Utku Uysal; Fethi Idiman; Egemen Idiman; Serkan Ozakbas; Sirel Karakas; Jared Bruce
Journal:  J Clin Neurol       Date:  2014-10-06       Impact factor: 3.077

Review 9.  Clinical implications of neuroplasticity - the role of rehabilitation in multiple sclerosis.

Authors:  Peter Flachenecker
Journal:  Front Neurol       Date:  2015-03-03       Impact factor: 4.003

10.  Concomitant Use of Neuroprotective Drugs in Neuro Rehabilitation of Multiple Sclerosis.

Authors:  Harika Dasari; Bharath Wootla; Arthur E Warrington; Moses Rodriguez
Journal:  Int J Phys Med Rehabil       Date:  2016-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.